Entering text into the input field will update the search result below

Regeneron and Sanofi's Dupixent shows treatment effect in mid-stage eosinophilic esophagitis study

  • Results from a Phase 2 clinical trial assessing Regeneron Pharmaceuticals (NASDAQ:REGN +0.7%) and Sanofi's (SNY +0.7%) DUPIXENT (dupilumab) in adult patients with moderate-to-severe eosinophilic esophagitis (EE) showed a treatment benefit. The data were presented at the World Congress of Gastroenterology in Orlando, FL.
  • The primary endpoint was a scale of swallowing difficulty called SDI score. At week 10, patients receiving dupilumab reported a significant improvement in the ability to swallow as measured by a three-point reduction (45% improvement) in SDI score, much better than placebo's 19% improvement (1.3-point reduction in SDI score) (p=0.0304).
  • Dupilumab has Orphan Drug status for EE. It was approved in May for eczema.

Recommended For You

About REGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
REGN--
Regeneron Pharmaceuticals, Inc.